| scholarly article | Q13442814 |
| P356 | DOI | 10.1136/ARD.2010.133488 |
| P698 | PubMed publication ID | 20829199 |
| P50 | author | Désirée van der Heijde | Q47262835 |
| Walter P Maksymowych | Q87727130 | ||
| P2093 | author name string | Maxime Dougados | |
| Juergen Braun | |||
| Joachim Sieper | |||
| Ruben Burgos-Vargas | |||
| Paternotte Simon | |||
| P433 | issue | 2 | |
| P304 | page(s) | 249-251 | |
| P577 | publication date | 2010-09-09 | |
| P1433 | published in | Annals of the Rheumatic Diseases | Q4767876 |
| P1476 | title | ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials/epidemiological studies in axial spondyloarthritis | |
| P478 | volume | 70 |
| Q24603648 | 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis |
| Q57623434 | A five-year prospective study of spinal radiographic progression and its predictors in men and women with ankylosing spondylitis |
| Q38638647 | A randomized double-blind placebo-controlled trial to investigate the effectiveness and safety of a novel green-lipped mussel extract -BioLex® -for managing pain in moderate to severe osteoarthritis of the hip and knee |
| Q92621847 | Alcohol consumption as a predictor of the progression of spinal structural damage in axial spondyloarthritis: data from the Catholic Axial Spondyloarthritis COhort (CASCO) |
| Q44915013 | Anti-tumor necrosis factor drug survival in axial spondyloarthritis is independent of the classification criteria. |
| Q52870848 | Axial spondyloarthritis. |
| Q42013856 | Axial spondyloarthritis: is there a treatment of choice? |
| Q38762450 | Baseline increased 18F-fluoride uptake lesions at vertebral corners on positron emission tomography predict new syndesmophyte development in ankylosing spondylitis: a 2-year longitudinal study |
| Q49548068 | Chronic but not inflammatory changes at the Achilles' tendon differentiate patients with peripheral spondyloarthritis from other diagnoses - Results from a prospective clinical trial. |
| Q24235846 | Combination therapy for pain management in inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis) |
| Q85315494 | Comment on "treat-to-target in spondyloarthritis: implications for clinical trial designs" |
| Q38001246 | Developments in therapies for spondyloarthritis |
| Q37465467 | Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1 |
| Q40204477 | Efficacy of long-term nonsteroidal antiinflammatory drug treatment on magnetic resonance imaging-determined bone marrow oedema in early, active axial spondyloarthritis patients |
| Q41958173 | Elevated calprotectin levels reveal bowel inflammation in spondyloarthritis. |
| Q34808170 | Evaluation of the nonsteroidal anti-inflammatory drug-sparing effect of etanercept in axial spondyloarthritis: results of the multicenter, randomized, double-blind, placebo-controlled SPARSE study |
| Q92305863 | Gastrointestinal risk factors and patient-reported outcomes of ankylosing spondylitis in Korea |
| Q56517190 | Harmonization, data management, and statistical issues related to prospective multicenter studies in Ankylosing spondylitis (AS): Experience from the Prospective Study Of Ankylosing Spondylitis (PSOAS) cohort |
| Q34446781 | Hydroxychloroquine in patients with inflammatory and erosive osteoarthritis of the hands (OA TREAT): study protocol for a randomized controlled trial |
| Q36611562 | IL-23/Th17 axis is not influenced by TNF-blocking agents in ankylosing spondylitis patients |
| Q36235821 | Impact of Dose Tapering of Tumor Necrosis Factor Inhibitor on Radiographic Progression in Ankylosing Spondylitis |
| Q89468184 | Impact of Tumor Necrosis Factor Inhibitor Versus Nonsteroidal Antiinflammatory Drug Treatment on Radiographic Progression in Early Ankylosing Spondylitis: Its Relationship to Inflammation Control During Treatment |
| Q91639335 | Indirect comparison of NSAIDs for ankylosing spondylitis: Network meta-analysis of randomized, double-blinded, controlled trials |
| Q24186403 | Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis) |
| Q90142748 | Nonsteroidal Anti-inflammatory Drug use is Associated with Incident Hypertension in Ankylosing Spondylitis |
| Q92934754 | Predictors of Assessment of Spondyloarthritis International Society (ASAS) Health Index in Axial Spondyloarthritis and Comparison of ASAS Health Index between Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis: Data from the Catholic |
| Q47094958 | Prevalence of and factors associated with renal dysfunction in rheumatoid arthritis patients: a cross-sectional study in community hospitals. |
| Q90748831 | Preventive effect of tumor necrosis factor inhibitors versus nonsteroidal anti-inflammatory drugs on uveitis in patients with ankylosing spondylitis |
| Q97426319 | Radiographic Progression in Patients With Ankylosing Spondylitis According to Uveitis Based on the Observation Study of Korean Spondyloarthropathy Registry |
| Q37456359 | Rate and Predisposing Factors for Sacroiliac Joint Radiographic Progression After a Two-Year Follow-up Period in Recent-Onset Spondyloarthritis |
| Q42380868 | Response to: 'Heterogeneity, consistency and model fit should be assessed in Bayesian network meta-analysis' by Wei et al. |
| Q38690333 | Sacroiliac radiographic progression in recent onset axial spondyloarthritis: the 5-year data of the DESIR cohort |
| Q60050041 | Sick leave and its predictors in ankylosing spondylitis: long-term results from the Outcome in Ankylosing Spondylitis International Study |
| Q35449032 | Spinal radiographic progression in patients with ankylosing spondylitis treated with TNF-α blocking therapy: a prospective longitudinal observational cohort study |
| Q47677081 | TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort. |
| Q37681895 | The impact of tumor necrosis factor α inhibitors on radiographic progression in ankylosing spondylitis |
| Q38124281 | Treatment challenges in axial spondylarthritis and future directions |
| Q47146126 | Which measuring site in ankylosing spondylitis is best to detect bone loss and what predicts the decline: results from a 5-year prospective study. |
| Q87082709 | [DGRh recommendations for the implementation of current security aspects in the NSAID treatment of musculoskeletal pain] |
Search more.